Richard D. Gelber, PhD

Richard D. Gelber, PhD

Researcher

Contact Information

Office Phone Number

617-632-3603

Fax

617-632-2444

Appointments

(617) 632-3603

Biography

Richard D. Gelber, PhD

Dr. Gelber received his PhD in operations research (major field: applied probability and statistics) from Cornell University in 1975. He has been at DFCI since 1977 and served as coordinating statistician for the DFCI Pediatric Acute Lymphoblastic Leukemia Consortium from 1977 to 2006 and statistical director of the Pediatric AIDS Clinical Trials Group from 1988 to 1998. He has been the Statistical Director for the International Breast Cancer Study Group since 1978.  In 1993, he was elected a fellow of the American Statistical Association. In addition, he was awarded an Honorary Doctorate in Medicine, University of Göteborg, Sweden in 1997.

Researcher

Physician

Professor of Pediatrics (Biostatistics), Harvard Medical School
Professor of Biostatistics, Harvard T.H. Chan School of Public Health

Recent Awards

  • Susan G. Komen Foundation Brinker Award for Scientific Distinction in Clinical Research

    2008

  • St. Gallen Conference Breast Cancer Award

    2009

  • ECCO (European CanCer Organisation) Clinical Research Award

    2011

  • European Institute of Oncology Award for Breast Cancer Research 2002
  • Jacqueline Seroussi Memorial Foundation for Cancer Research Award 2005

Research

    Q-TWiST, Quality-Adjusted Survival, Subpopulation Treatment Effect Pattern Plot (STEPP) and Breast Cancer Clinical Trials

    Dr. Gelber developed the Q-TWiST method (Quality-adjusted Time Without Symptoms of disease and Toxicity of treatment) for incorporating quality-of-life considerations into treatment comparisons. This quality-adjusted survival technique provides a framework to balance the benefits of disease control against the costs of treatment side effects using threshold utility analysis and patient preferences. He also created the STEPP method (Subpopulation Treatment Effect Pattern Plot) which uses data from randomized clinical trials to graphically illustrate the pattern of differences in treatment effectiveness as a function of a covariate of interest. Dr. Gelber has directed the Statistical Center for the International Breast Cancer Study Group (IBCSG) since 1978. This consortium of institutions conducts Phase III clinical trials for adjuvant therapy for breast cancer. In addition, he is the senior biostatistician for two three major studies of adjuvant treatment for HER2-positive breast cancer conducted by the Breast International Group (BIG: the HERA and, ALTTO and APHINITY trials).

    Research Departments

    Publications

      • Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. N Engl J Med. 2023 May 04; 388(18):1645-1656. View in: Pubmed

      • Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. J Clin Oncol. 2023 06 01; 41(16):2998-3008. View in: Pubmed

      • Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy. J Clin Oncol. 2023 06 01; 41(16):2988-2997. View in: Pubmed

      • Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis. Semin Oncol. 2023 Feb-Apr; 50(1-2):34-39. View in: Pubmed

      • Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials. Breast. 2023 Jun; 69:258-264. View in: Pubmed

      • Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. Eur J Cancer. 2023 03; 181:92-101. View in: Pubmed

      • Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. J Clin Oncol. 2023 03 01; 41(7):1376-1382. View in: Pubmed

      • Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. J Clin Oncol. 2023 03 01; 41(7):1370-1375. View in: Pubmed

      • Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations. JAMA Oncol. 2022 11 01; 8(11):1668-1675. View in: Pubmed

      • Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022 12; 33(12):1250-1268. View in: Pubmed

      • Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022 08 01; 5(8):e2226252. View in: Pubmed

      • Sex and cancer immunotherapy: Current understanding and challenges. Cancer Cell. 2022 07 11; 40(7):695-700. View in: Pubmed

      • Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. Eur J Cancer. 2022 05; 166:219-228. View in: Pubmed

      • Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ Breast Cancer. 2022 Feb 16; 8(1):18. View in: Pubmed

      • Correction to: Tolerability and toxicity of trastuzumab or trastuzumab?+?lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D). Breast Cancer Res Treat. 2022 Jan; 191(1):225. View in: Pubmed

      • Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021 12 21; 375:e066381. View in: Pubmed

      • Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. Ann Oncol. 2021 10; 32(10):1256-1266. View in: Pubmed

      • Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Breast. 2021 Oct; 59:327-338. View in: Pubmed

      • Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations. Breast. 2021 Oct; 59:94-101. View in: Pubmed

      • Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021 06 24; 384(25):2394-2405. View in: Pubmed

      • Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2375-2385. View in: Pubmed

      • Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. Clin Cancer Res. 2021 08 01; 27(15):4311-4324. View in: Pubmed

      • Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. Br J Cancer. 2021 07; 125(1):38-47. View in: Pubmed

      • Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). Eur J Cancer. 2021 05; 148:287-296. View in: Pubmed

      • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. J Clin Oncol. 2021 05 01; 39(13):1448-1457. View in: Pubmed

      • Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial. Cancer. 2021 03 01; 127(5):700-708. View in: Pubmed

      • Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. Breast Cancer Res Treat. 2021 Feb; 185(3):697-707. View in: Pubmed

      • Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. J Clin Oncol. 2020 12 01; 38(34):4120-4129. View in: Pubmed

      • Tolerability and toxicity of trastuzumab or trastuzumab?+?lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D). Breast Cancer Res Treat. 2021 Jan; 185(1):107-116. View in: Pubmed

      • Are We RESPECTing Older Patients With Breast Cancer? J Clin Oncol. 2020 11 10; 38(32):3727-3730. View in: Pubmed

      • Estimation of historical control rate for a single arm de-escalation study - Application to the POSITIVE trial. Breast. 2020 Oct; 53:1-7. View in: Pubmed

      • Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2020 Jun; 181(2):347-359. View in: Pubmed

      • The legacy of Professor Aron Goldhirsch. Ann Oncol. 2020 06; 31(6):671-673. View in: Pubmed

      • Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. Br J Cancer. 2020 Mar; 122(7):1119. View in: Pubmed

      • Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. Breast Cancer Res. 2019 12 30; 21(1):153. View in: Pubmed

      • Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial. Ann Oncol. 2019 Sep; 30(9):1507-1513. View in: Pubmed

      • Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer? Ann Oncol. 2009 Oct; 20(10):1751-1752. View in: Pubmed

      • Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. Ann Oncol. 2012 Nov; 23(11):2852-2858. View in: Pubmed

      • Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. Ann Oncol. 2012 May; 23(5):1138-1144. View in: Pubmed

      • Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol. 2012 Nov; 23(11):2843-2851. View in: Pubmed

      • Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment. Ann Oncol. 2019 Apr; 30(4):653-655. View in: Pubmed

      • International consensus on treatment of early breast cancer: radiotherapy issues A response to 'International expert consensus on radiotherapy of early breast cancer'. Ann Oncol. 2007 Dec; 18(12):2044-2045. View in: Pubmed

      • Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. J Clin Oncol. 2020 04 20; 38(12):1293-1303. View in: Pubmed

      • A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. Breast Cancer Res Treat. 2020 Jan; 179(1):161-171. View in: Pubmed

      • Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Clin Breast Cancer. 2020 04; 20(2):174-181.e3. View in: Pubmed

      • Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial. Ann Oncol. 2019 09 01; 30(9):1507-1513. View in: Pubmed

      • Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. Eur J Cancer. 2019 09; 118:169-177. View in: Pubmed

      • Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2019 08 01; 111(8):772-781. View in: Pubmed

      • Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial. Breast Cancer Res Treat. 2019 Aug; 177(1):103-114. View in: Pubmed

      • Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. Br J Cancer. 2019 05; 120(10):959-967. View in: Pubmed

      • Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment. Ann Oncol. 2019 04 01; 30(4):653-655. View in: Pubmed

      • Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. Anticancer Res. 2019 Feb; 39(2):797-802. View in: Pubmed

      • Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. J Natl Cancer Inst. 2019 02 01; 111(2):210-213. View in: Pubmed

      • PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer? NPJ Breast Cancer. 2019; 5:1. View in: Pubmed

      • Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. J Natl Cancer Inst. 2019 01 01; 111(1):86-94. View in: Pubmed

      • Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. J Clin Oncol. 2019 02 10; 37(5):386-395. View in: Pubmed

      • Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. J Clin Oncol. 2019 01 10; 37(2):105-114. View in: Pubmed

      • Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. Cancer. 2019 01 15; 125(2):307-316. View in: Pubmed

      • Reply to Jeffrey Graham, Omar Abdel-Rahman, Toni K. Choueiri, and Daniel Y.C. Heng's Letter to the Editor re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018;19:737-46: Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC Database Consortium. Eur Urol. 2019 02; 75(2):e34-e35. View in: Pubmed

      • Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018 10; 19(10):1385-1393. View in: Pubmed

      • Sex as a predictor of response to cancer immunotherapy - Authors' reply. Lancet Oncol. 2018 08; 19(8):e380-e381. View in: Pubmed

      • Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):122-137. View in: Pubmed

      • Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. Lancet Oncol. 2018 06; 19(6):737-746. View in: Pubmed

      • Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. Breast Cancer Res Treat. 2018 Jul; 170(2):351-360. View in: Pubmed

      • Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. Clin Cancer Res. 2018 07 01; 24(13):3079-3086. View in: Pubmed

      • Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J Clin Oncol. 2018 04 10; 36(11):1073-1079. View in: Pubmed

      • Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial. Int J Radiat Oncol Biol Phys. 2018 06 01; 101(2):316-324. View in: Pubmed

      • Meta-STEPP with random effects. Res Synth Methods. 2018 Jun; 9(2):312-317. View in: Pubmed

      • Concerns about cardiotoxicity in the HERA trial - Authors' reply. Lancet. 2017 12 23; 390(10114):2767-2768. View in: Pubmed

      • Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018 01; 19(1):127-138. View in: Pubmed

      • Assessing health-related quality of life in patients with breast cancer: a reply to Maratia et al. Qual Life Res. 2018 01; 27(1):149-152. View in: Pubmed

      • Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol. 2017 Sep 01; 28(9):2225-2232. View in: Pubmed

      • Oncology Physicians' Perspectives on Practices and Barriers to Fertility Preservation and the Feasibility of a Prospective Study of Pregnancy After Breast Cancer. J Adolesc Young Adult Oncol. 2017 Sep; 6(3):429-434. View in: Pubmed

      • Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol. 2017 Sep 20; 35(27):3113-3122. View in: Pubmed

      • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017 Jul 13; 377(2):122-131. View in: Pubmed

      • Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer. J Clin Oncol. 2017 Sep 20; 35(27):3160-3168. View in: Pubmed

      • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017 03 25; 389(10075):1195-1205. View in: Pubmed

      • Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. J Clin Oncol. 2017 Apr 10; 35(11):1179-1188. View in: Pubmed

      • Reply to L. Moscetti. J Clin Oncol. 2017 05 10; 35(14):1628. View in: Pubmed

      • Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast Cancer Res. 2016 11 08; 18(1):110. View in: Pubmed

      • Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VII. Int J Radiat Oncol Biol Phys. 2016 10 01; 96(2):273-279. View in: Pubmed

      • Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial. Ann Surg Oncol. 2017 Feb; 24(2):398-406. View in: Pubmed

      • Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Res Treat. 2016 07; 158(2):323-31. View in: Pubmed

      • Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. J Clin Oncol. 2016 10 01; 34(28):3400-8. View in: Pubmed

      • Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. J Clin Oncol. 2016 07 20; 34(21):2452-9. View in: Pubmed

      • Subpopulation Treatment Effect Pattern Plot (STEPP) analysis for continuous, binary, and count outcomes. Clin Trials. 2016 08; 13(4):382-90. View in: Pubmed

      • Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer. 2016 04 26; 114(9):956-64. View in: Pubmed

      • Meta-STEPP: subpopulation treatment effect pattern plot for individual patient data meta-analysis. Stat Med. 2016 09 20; 35(21):3704-16. View in: Pubmed

      • Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol. 2016 07 01; 34(19):2221-31. View in: Pubmed

      • Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 2016 05 10; 34(14):1601-10. View in: Pubmed

      • Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol. 2016 Mar 20; 34(9):927-35. View in: Pubmed

      • Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. Breast Cancer Res Treat. 2016 Jan; 155(1):127-32. View in: Pubmed

      • Reply to A. Oguz et al. J Clin Oncol. 2016 Feb 20; 34(6):640-1. View in: Pubmed

      • Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. J Clin Oncol. 2016 Apr 01; 34(10):1034-42. View in: Pubmed

      • ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. Breast Cancer Res Treat. 2015 Dec; 154(3):543-55. View in: Pubmed

      • Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP. Clin Trials. 2016 Apr; 13(2):169-79. View in: Pubmed

      • Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Res Treat. 2015 Nov; 154(2):275-86. View in: Pubmed

      • Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. Ann Oncol. 2015 Dec; 26(12):2442-9. View in: Pubmed

      • Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. J Clin Oncol. 2015 Sep 01; 33(25):2772-9. View in: Pubmed

      • Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors = 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. J Clin Oncol. 2015 Aug 20; 33(24):2600-8. View in: Pubmed

      • Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015 Jul; 16(7):848-58. View in: Pubmed

      • Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015 Aug; 26(8):1533-46. View in: Pubmed

      • Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015 03 05; 372(10):923-32. View in: Pubmed

      • Pregnancy after breast cancer: Are young patients willing to participate in clinical studies? Breast. 2015 Jun; 24(3):201-7. View in: Pubmed

      • Marvin Zelen, 1927-2014. Clin Trials. 2015 Apr; 12(2):183-4. View in: Pubmed

      • Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29; 372(5):436-46. View in: Pubmed

      • Chemotherapy benefit for 'ER-positive' breast cancer and contamination of nonluminal subtypes—waiting for TAILORx and RxPONDER. Ann Oncol. 2015 Jan; 26(1):70-74. View in: Pubmed

      • The AURORA initiative for metastatic breast cancer. Br J Cancer. 2014 Nov 11; 111(10):1881-7. View in: Pubmed

      • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014 Sep; 15(10):1137-46. View in: Pubmed

      • First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T?L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol. 2014 Jun 20; 32(18_suppl):LBA4. View in: Pubmed

      • Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance). J Clin Oncol. 2014 Jun 20; 32(18_suppl):LBA505. View in: Pubmed

      • Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. J Clin Oncol. 2014 Jun 20; 32(18_suppl):LBA1. View in: Pubmed

      • Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol. 2014 Jul 10; 32(20):2159-65. View in: Pubmed

      • Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10; 371(2):107-18. View in: Pubmed

      • Time to initiation of adjuvant chemotherapy for early breast cancer and outcome: the earlier, the better? J Clin Oncol. 2014 Mar 10; 32(8):717-9. View in: Pubmed

      • Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. Breast Cancer Res Treat. 2014 Apr; 144(2):321-9. View in: Pubmed

      • Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol. 2014 Feb; 15(2):156-63. View in: Pubmed

      • Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. Breast Cancer Res Treat. 2014 Feb; 143(3):485-92. View in: Pubmed

      • Reply to D. Serraino et al. J Clin Oncol. 2014 Jan 10; 32(2):161. View in: Pubmed

      • Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat. 2014 Jan; 143(1):159-69. View in: Pubmed

      • Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast. 2013 Dec; 22(6):1094-100. View in: Pubmed

      • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013 Sep; 24(9):2206-23. View in: Pubmed

      • Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol. 2013 Sep 01; 31(25):3083-90. View in: Pubmed

      • 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013 Sep 21; 382(9897):1021-8. View in: Pubmed

      • Challenges of guarantee-time bias. J Clin Oncol. 2013 Aug 10; 31(23):2963-9. View in: Pubmed

      • Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol. 2013 Jul 20; 31(21):2692-8. View in: Pubmed

      • Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. J Clin Oncol. 2013 Jun 01; 31(16):1954-60. View in: Pubmed

      • Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013 Apr; 14(4):297-305. View in: Pubmed

      • Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial. Breast. 2013 Apr; 22(2):130-137. View in: Pubmed

      • CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol. 2013 Mar; 14(3):244-8. View in: Pubmed

      • Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial. Ann Oncol. 2013 May; 24(5):1203-11. View in: Pubmed

      • Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. Breast Cancer Res. 2012 Nov 05; 14(6):R143. View in: Pubmed

      • Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol. 2012 Nov 10; 30(32):3967-75. View in: Pubmed

      • Breast cancer: Anastrozole and fulvestrant--combination to unlock efficacy. Nat Rev Clin Oncol. 2012 Oct; 9(10):556-7. View in: Pubmed

      • Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. Ann Oncol. 2012 Nov; 23(11):2852-2858. View in: Pubmed

      • A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer. Breast. 2012 Oct; 21(5):621-8. View in: Pubmed

      • Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol. 2012 Nov; 23(11):2843-2851. View in: Pubmed

      • Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. Br J Cancer. 2012 May 08; 106(10):1618-25. View in: Pubmed

      • CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst. 2012 Mar 21; 104(6):441-51. View in: Pubmed

      • Health-related quality of life among children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Oct; 59(4):717-24. View in: Pubmed

      • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012 Feb 18; 379(9816):633-40. View in: Pubmed

      • Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol. 2011 Nov; 12(12):1101-8. View in: Pubmed

      • Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. Ann Oncol. 2012 May; 23(5):1138-1144. View in: Pubmed

      • Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011 Aug; 22(8):1736-47. View in: Pubmed

      • Pregnancy after breast cancer: if you wish, ma'am. Breast Cancer Res Treat. 2011 Sep; 129(2):309-17. View in: Pubmed

      • Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res. 2011 May 26; 13(3):209. View in: Pubmed

      • Bone mineral density (BMD) in participants (pts) of trial BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence. J Clin Oncol. 2011 May 20; 29(15_suppl):516. View in: Pubmed

      • ESR1 and ESR2 polymorphisms in BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence for early breast cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):1002. View in: Pubmed

      • Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011 Mar; 12(3):236-44. View in: Pubmed

      • Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol. 2011 Oct; 22(10):2201-7. View in: Pubmed

      • Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Ann Oncol. 2011 Oct; 22(10):2216-26. View in: Pubmed

      • Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol. 2011 Mar 20; 29(9):1117-24. View in: Pubmed

      • Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Ann Oncol. 2011 Sep; 22(9):1981-1987. View in: Pubmed

      • Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat. 2011 Feb; 126(1):221-6. View in: Pubmed

      • Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot. J Clin Oncol. 2010 Oct 10; 28(29):4539-44. View in: Pubmed

      • CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D. Breast Cancer Res Treat. 2010 Aug; 123(1):163-9. View in: Pubmed

      • Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol. 2010 Jun 20; 28(18):2966-73. View in: Pubmed

      • Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast. 2010 Oct; 19(5):388-95. View in: Pubmed

      • Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat. 2010 Aug; 123(1):303-10. View in: Pubmed

      • The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat. 2010 Jan; 119(1):145-53. View in: Pubmed

      • Facilitating consensus by examining patterns of treatment effects. Breast. 2009 Oct; 18 Suppl 3:S2-8. View in: Pubmed

      • Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009 Aug 20; 361(8):766-76. View in: Pubmed

      • Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Ann Oncol. 2010 Feb; 21(2):245-254. View in: Pubmed

      • The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. BMC Med Genomics. 2009 Jul 02; 2:40. View in: Pubmed

      • Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009 Aug; 20(8):1319-29. View in: Pubmed

      • Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study. J Clin Oncol. 2009 Aug 01; 27(22):3620-6. View in: Pubmed

      • Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clin Trials. 2009 Jun; 6(3):272-87. View in: Pubmed

      • Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009 May 28; 360(22):2367; author reply 2369-70. View in: Pubmed

      • Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol. 2009 Sep; 20(9):1489-1498. View in: Pubmed

      • The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol. 2009 Aug; 20(8):1344-51. View in: Pubmed

      • Evaluation of Adjuvant! Online to predict the effect of optimal endocrine therapy (ovarian function suppression plus tamoxifen) for premenopausal breast cancer patients with estrogen-receptor-positive breast cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):585. View in: Pubmed

      • A small sample study of the STEPP approach to assessing treatment-covariate interactions in survival data. Stat Med. 2009 Apr 15; 28(8):1255-68. View in: Pubmed

      • Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol. 2009 Jun 20; 27(18):2962-9. View in: Pubmed

      • Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. Breast Cancer Res Treat. 2010 May; 121(1):211-8. View in: Pubmed

      • Bone Quality Test (BQT) scores of fingernails in postmenopausal patients treated with adjuvant letrozole or tamoxifen for early breast cancer. Breast. 2009 Apr; 18(2):84-8. View in: Pubmed

      • Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century. Breast Cancer Res Treat. 2009 Sep; 117(2):319-24. View in: Pubmed

      • Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group. Eur J Cancer. 2009 Mar; 45(4):561-71. View in: Pubmed

      • Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008 Dec 01; 26(34):5569-75. View in: Pubmed

      • Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat. 2009 Aug; 116(3):491-500. View in: Pubmed

      • Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat. 2009 Jul; 116(2):359-69. View in: Pubmed

      • Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol. 2008 Aug 20; 26(24):3913-5. View in: Pubmed

      • Another STEPP in the right direction. J Clin Oncol. 2008 Aug 01; 26(22):3813-4; author reply 3814-5. View in: Pubmed

      • Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial. Ann Oncol. 2008 Nov; 19(11):1837-41. View in: Pubmed

      • A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. Clin Breast Cancer. 2008 Jun; 8(3):287-92. View in: Pubmed

      • Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008 Jun 20; 26(18):3006-14. View in: Pubmed

      • Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Ann Oncol. 2008 Aug; 19(8):1393-1401. View in: Pubmed

      • Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. J Clin Oncol. 2008 Mar 20; 26(9):1404-10. View in: Pubmed

      • Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol. 2008 Apr 20; 26(12):1972-9. View in: Pubmed

      • Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol. 2008 Jul; 19(7):1231-1241. View in: Pubmed

      • Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol. 2008 Jun; 19(6):1090-6. View in: Pubmed

      • Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat. 2009 Jan; 113(1):137-44. View in: Pubmed

      • Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst. 2008 Feb 06; 100(3):207-12. View in: Pubmed

      • Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst. 2008 Jan 16; 100(2):121-33. View in: Pubmed

      • Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 2008 Jan 05; 371(9606):29-40. View in: Pubmed

      • Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008 Jan; 9(1):23-8. View in: Pubmed

      • Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. Br J Cancer. 2008 Jan 15; 98(1):25-33. View in: Pubmed

      • Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol. 2007 Dec 20; 25(36):5715-22. View in: Pubmed

      • Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol. 2008 Mar; 19(3):465-72. View in: Pubmed

      • Using clinical trial data to tailor adjuvant treatments for individual patients. Breast. 2007 Dec; 16 Suppl 2:S98-104. View in: Pubmed

      • Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007 Sep 01; 25(25):3846-52. View in: Pubmed

      • Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007 Sep 01; 25(25):3859-65. View in: Pubmed

      • Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression. Cancer Chemother Pharmacol. 2008 May; 61(6):965-71. View in: Pubmed

      • Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007 Jul; 18(7):1133-44. View in: Pubmed

      • Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA. BMC Infect Dis. 2007 Jun 20; 7:60. View in: Pubmed

      • Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007 May 20; 25(15):2127-32. View in: Pubmed

      • Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer. 2007 Jul; 43(11):1646-53. View in: Pubmed

      • Problems with the progesterone receptor in practice? J Clin Oncol. 2007 May 20; 25(15):1957-9. View in: Pubmed

      • Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. Ann Oncol. 2007 Jul; 18(7):1177-84. View in: Pubmed

      • The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. J Clin Oncol. 2007 May 20; 25(15):2019-26. View in: Pubmed

      • Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol. 2007 May; 18(5):859-67. View in: Pubmed

      • CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol. 2007 Apr; 18(4):701-8. View in: Pubmed

      • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007 Jan 06; 369(9555):29-36. View in: Pubmed

      • Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007 Feb 10; 25(5):486-92. View in: Pubmed

      • Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. J Clin Oncol. 2007 Jan 20; 25(3):263-70. View in: Pubmed

      • Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 2006 Nov 01; 98(21):1571-81. View in: Pubmed

      • First--select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol. 2006 Dec; 17(12):1772-6. View in: Pubmed

      • Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007 Feb 01; 109(3):896-904. View in: Pubmed

      • BIG 1-98: A randomized double-blind phase III study comparing letrozole and tamoxifen given in sequence vs. alone as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):LBA528. View in: Pubmed

      • Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006 Jun; 17(6):935-44. View in: Pubmed

      • Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol. 2006 Mar 20; 24(9):1332-41. View in: Pubmed

      • Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer. 2006 Feb 01; 106(3):505-13. View in: Pubmed

      • Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol. 2006 Jan 20; 24(3):370-8. View in: Pubmed

      • Estimation in regression models for longitudinal binary data with outcome-dependent follow-up. Biostatistics. 2006 Jul; 7(3):469-85. View in: Pubmed

      • A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005 Dec 29; 353(26):2747-57. View in: Pubmed

      • Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol. 2006 Jan 20; 24(3):337-44. View in: Pubmed

      • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005 Oct 20; 353(16):1659-72. View in: Pubmed

      • Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI. J Clin Oncol. 2005 Oct 01; 23(28):7089-97. View in: Pubmed

      • Predicting response to systemic treatments: learning from the past to plan for the future. Breast. 2005 Dec; 14(6):582-93. View in: Pubmed

      • Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005 Oct; 16(10):1569-83. View in: Pubmed

      • Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet. 2005 Sep 24-30; 366(9491):1108-10. View in: Pubmed

      • What are the long-term effects of chemotherapy and hormonal therapy for early breast cancer? Nat Clin Pract Oncol. 2005 Sep; 2(9):440-1. View in: Pubmed

      • A multistate Markov chain model for longitudinal, categorical quality-of-life data subject to non-ignorable missingness. Stat Med. 2005 Aug 15; 24(15):2317-34. View in: Pubmed

      • Delayed premature menopause following chemotherapy for early stage breast cancer: Long-term results from IBCSG Trial V. J Clin Oncol. 2005 Jun; 23(16_suppl):687. View in: Pubmed

      • BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):511. View in: Pubmed

      • Prediction of cancer outcome with microarrays. Lancet. 2005 May 14-20; 365(9472):1685-6; author reply 1686. View in: Pubmed

      • Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005 Apr 20; 23(12):2629-36. View in: Pubmed

      • Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. Ann Oncol. 2005 May; 16(5):716-25. View in: Pubmed

      • Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol. 2005 Mar 10; 23(8):1736-50. View in: Pubmed

      • Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience. J Clin Oncol. 2005 Mar 01; 23(7):1390-400. View in: Pubmed

      • Life with consequences of breast cancer: pregnancy during and after endocrine therapies. Breast. 2004 Dec; 13(6):443-5. View in: Pubmed

      • Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol. 2004 Dec; 15(12):1749-59. View in: Pubmed

      • Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. Br J Cancer. 2004 Nov 29; 91(11):1893-901. View in: Pubmed

      • American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005 Jan 20; 23(3):619-29. View in: Pubmed

      • Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res. 2004 Oct 01; 10(19):6622-8. View in: Pubmed

      • Echocardiographic (Echo) monitoring of myocardial injury during doxorubicin (DOX) therapy for childhood acute lymphoblastic leukemia (ALL). J Clin Oncol. 2004 Jul 15; 22(14_suppl):8505. View in: Pubmed

      • The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004 Jul 08; 351(2):145-53. View in: Pubmed

      • The impact of race/ethnicity on mother-to-child HIV transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316. J Acquir Immune Defic Syndr. 2004 Jul 01; 36(3):800-7. View in: Pubmed

      • Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics. 2004 Jul; 5(3):465-81. View in: Pubmed

      • Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity. J Clin Oncol. 2004 Jul 01; 22(13):2701-7. View in: Pubmed

      • Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO). Strahlenther Onkol. 2004 Jun; 180 Suppl 1:89-108. View in: Pubmed

      • Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol. 2004 Jun; 15(6):875-84. View in: Pubmed

      • Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol. 2004 Feb; 190(2):506-16. View in: Pubmed

      • A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer. J Biopharm Stat. 2004 Feb; 14(1):111-24. View in: Pubmed

      • Lesson learned from high-dose chemotherapy for high-risk breast cancer (What you see is what you mean). Ann Oncol. 2004 Feb; 15(2):355-6. View in: Pubmed

      • Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst. 2003 Dec 17; 95(24):1833-46. View in: Pubmed

      • Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV. J Clin Oncol. 2003 Dec 15; 21(24):4517-23. View in: Pubmed

      • Preoperative systemic treatment: prediction of responsiveness. Breast. 2003 Dec; 12(6):538-42. View in: Pubmed

      • Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer. Breast. 2003 Dec; 12(6):569-82. View in: Pubmed

      • Tailoring adjuvant treatments for the individual breast cancer patient. Breast. 2003 Dec; 12(6):558-68. View in: Pubmed

      • Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003 Oct 01; 21(19):3616-22. View in: Pubmed

      • Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment. J Clin Oncol. 2003 Aug 01; 21(15):2953-60. View in: Pubmed

      • Systemic treatments for women with breast cancer: outcome with relation to screening for the disease. Ann Oncol. 2003 Aug; 14(8):1212-4. View in: Pubmed

      • Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003 Sep 01; 21(17):3357-65. View in: Pubmed

      • Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. J Acquir Immune Defic Syndr. 2003 Jun 01; 33(2):153-6. View in: Pubmed

      • American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003 Jul 01; 21(13):2597-9. View in: Pubmed

      • Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol. 2003 Apr 01; 21(7):1205-13. View in: Pubmed

      • Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V. Cancer. 2003 Apr 01; 97(7):1591-600. View in: Pubmed

      • Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker? Cancer. 2003 Mar 01; 97(5):1321-31. View in: Pubmed

      • Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002 Dec 01; 20(23):4517-22. View in: Pubmed

      • Parameter estimation in longitudinal studies with outcome-dependent follow-up. Biometrics. 2002 Sep; 58(3):621-30. View in: Pubmed

      • Overhauling the breast cancer overview: are subsets subversive? Lancet Oncol. 2002 Sep; 3(9):525-6. View in: Pubmed

      • Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J. 2002 Sep; 21(9):835-8. View in: Pubmed

      • Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002 Jul 10; 288(2):189-98. View in: Pubmed

      • Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis. 2002 Jul 15; 186(2):181-8. View in: Pubmed

      • Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer. 2002 Jun 05; 86(11):1705-14. View in: Pubmed

      • Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol. 2002 Apr 01; 20(7):1786-92. View in: Pubmed

      • Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol. 2002 Mar 15; 20(6):1677-82. View in: Pubmed

      • Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. J Clin Oncol. 2002 Jan 01; 20(1):237-46. View in: Pubmed

      • Endocrine therapy of breast cancer. Ann Oncol. 2002; 13 Suppl 4:61-8. View in: Pubmed

      • Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol. 2001 Nov 01; 19(21):4141-9. View in: Pubmed

      • Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol. 2001 Sep 15; 19(18):3817-27. View in: Pubmed

      • Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet. 2001 Jul 28; 358(9278):277-86. View in: Pubmed

      • Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01. Cancer. 2001 Jul 01; 92(1):15-22. View in: Pubmed

      • Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol. 2001 Jun 15; 19(12):3066-72. View in: Pubmed

      • Joint regression analysis of survival and quality-adjusted survival. Biometrics. 2001 Jun; 57(2):376-82. View in: Pubmed

      • Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol. 2001 Mar 15; 19(6):1671-5. View in: Pubmed

      • Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001 Mar 01; 97(5):1211-8. View in: Pubmed

      • Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol. 2001 Feb 15; 19(4):1064-70. View in: Pubmed

      • Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol. 2001 Feb 15; 19(4):1040-6. View in: Pubmed

      • Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr. 2001; (30):44-51. View in: Pubmed

      • Tubular carcinoma of the breast: prognosis and response to adjuvant systemic therapy. ANZ J Surg. 2001 Jan; 71(1):27-31. View in: Pubmed

      • Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol. 2000 Dec 01; 18(23):3925-35. View in: Pubmed

      • Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000 Dec; 14(12):2247-56. View in: Pubmed

      • Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group. J Clin Oncol. 2000 Nov 15; 18(22):3768-74. View in: Pubmed

      • A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med. 2000 Oct 15; 19(19):2595-609. View in: Pubmed

      • Taxanes as adjuvant for breast cancer. Lancet. 2000 Aug 05; 356(9228):507-8. View in: Pubmed

      • Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet. 2000 May 27; 355(9218):1869-74. View in: Pubmed

      • Who gets chemotherapy for metastatic lung cancer? Chest. 2000 May; 117(5):1239-46. View in: Pubmed

      • Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer. 2000 Apr 15; 88(8):1964-9. View in: Pubmed

      • Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol. 2000 Apr; 18(7):1412-22. View in: Pubmed

      • Systemic adjuvant treatment for premenopausal node-negative breast cancer. The International Breast Cancer Study Group. Eur J Cancer. 2000 Mar; 36(4):549-50. View in: Pubmed

      • Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol. 2000 Feb; 18(3):584-90. View in: Pubmed

      • Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet. 1999 Sep 11; 354(9182):896-900. View in: Pubmed

      • Mode of delivery and the risk of vertical transmission of HIV-1. N Engl J Med. 1999 Jul 15; 341(3):206-7. View in: Pubmed

      • Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. International Breast Cancer Study Group. Lancet. 1999 Jul 10; 354(9173):130-1. View in: Pubmed

      • Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: A Q-TWiST analysis of the Pediatric Oncology Group Study 8821. J Clin Oncol. 1999 Jul; 17(7):2144-52. View in: Pubmed

      • Induction failure in acute lymphoblastic leukemia of childhood. Cancer. 1999 Mar 15; 85(6):1395-404. View in: Pubmed

      • Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 1999 Jan-Feb; 21(1):6-12. View in: Pubmed

      • Subsets within the chemotherapy overview. International Breast Cancer Study Group. Lancet. 1998 Nov 28; 352(9142):1783-4. View in: Pubmed

      • Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst. 1998 Nov 04; 90(21):1601-8. View in: Pubmed

      • The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer. 1998 Oct 15; 83(8):1529-39. View in: Pubmed

      • Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. Eur J Cancer. 1998 Oct; 34(11):1693-700. View in: Pubmed

      • Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG). Br J Cancer. 1998 Sep; 78(5):686-93. View in: Pubmed

      • New treatments for breast cancer: breakthroughs for patient care or just steps in the right direction? Ann Oncol. 1998 Sep; 9(9):973-6. View in: Pubmed

      • Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop. Eur J Cancer. 1998 Aug; 34(9):1317-33. View in: Pubmed

      • Second malignancies in patients treated for childhood acute lymphoblastic leukemia. J Clin Oncol. 1998 Aug; 16(8):2848-53. View in: Pubmed

      • Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. J Clin Oncol. 1998 Jul; 16(7):2339-44. View in: Pubmed

      • Quality adjusted survival analysis with repeated quality of life measures. Stat Med. 1998 Jun 15; 17(11):1215-29. View in: Pubmed

      • Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG). Ann Oncol. 1998 May; 9(5):489-93. View in: Pubmed

      • Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group. J Clin Oncol. 1998 Apr; 16(4):1358-62. View in: Pubmed

      • Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer. 1998 Apr; 34(5):632-40. View in: Pubmed

      • Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: practical issues and factors associated with missing data. Stat Med. 1998 Mar 15-Apr 15; 17(5-7):587-601. View in: Pubmed

      • Radiotherapy and chemotherapy in high-risk breast cancer. N Engl J Med. 1998 Jan 29; 338(5):330-1; author reply 331-2. View in: Pubmed

      • International Consensus Panel on the treatment of primary breast cancer. V: Update 1998. Recent Results Cancer Res. 1998; 152:481-97. View in: Pubmed

      • Quality of life assessment in the adjuvant setting: is it relevant? International Breast Cancer Study Group. Recent Results Cancer Res. 1998; 152:373-89. View in: Pubmed

      • Survival benefit in melanoma. J Clin Oncol. 1998 Jan; 16(1):388-9. View in: Pubmed

      • Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer. 1997 Dec 15; 80(12):2285-95. View in: Pubmed

      • Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group. Eur J Cancer. 1997 Dec; 33(14):2321-5. View in: Pubmed

      • Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group. Ann Oncol. 1997 Sep; 8(9):825-35. View in: Pubmed

      • Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Ann Oncol. 1997 Aug; 8(8):751-6. View in: Pubmed

      • Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol. 1997 May; 15(5):1923-31. View in: Pubmed

      • Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1996 Oct; 14(10):2666-73. View in: Pubmed

      • A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst. 1996 Aug 07; 88(15):1039-45. View in: Pubmed

      • Endocrine therapies of breast cancer. Semin Oncol. 1996 Aug; 23(4):494-505. View in: Pubmed

      • Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group. Int J Radiat Oncol Biol Phys. 1996 Jul 01; 35(4):649-59. View in: Pubmed

      • Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet. 1996 May 11; 347(9011):1279-84. View in: Pubmed

      • Randomized study of the tolerance and efficacy of high- versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials Group 128). Pediatric AIDS Clinical Trials Group. J Infect Dis. 1996 May; 173(5):1097-106. View in: Pubmed

      • Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet. 1996 Apr 20; 347(9008):1066-71. View in: Pubmed

      • Gemcitabine for pancreatic cancer: how hard to look for clinical benefit? An American perspective. Ann Oncol. 1996 Apr; 7(4):335-7. View in: Pubmed

      • Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial. Med Care. 1996 Mar; 34(3):234-48. View in: Pubmed

      • The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group. Ann Oncol. 1996 Mar; 7(3):245-50. View in: Pubmed

      • Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996 Jan; 14(1):18-24. View in: Pubmed

      • Adjuvant systemic therapy: the issues of timing and sequence. Recent Results Cancer Res. 1996; 140:201-13. View in: Pubmed

      • IX. International consensus conference on primary treatment of breast cancer. Recent Results Cancer Res. 1996; 140:325-35. View in: Pubmed

      • AZT trial in Thailand. Science. 1995 Nov 10; 270(5238):899-900. View in: Pubmed

      • Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst. 1995 Oct 04; 87(19):1441-5. View in: Pubmed

      • Routine tests during follow-up of patients after primary treatment for operable breast cancer. International (Ludwig) Breast Cancer Study Group (IBCSG) Ann Oncol. 1995 Oct; 6(8):769-76. View in: Pubmed

      • Fifth International Conference on Adjuvant Therapy of Breast Cancer, St Gallen, March 1995. International Consensus Panel on the Treatment of Primary Breast Cancer. Eur J Cancer. 1995 Oct; 31A(11):1754-9. View in: Pubmed

      • A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. International Breast Cancer Study Group. Stat Med. 1995 Aug 30; 14(16):1771-84. View in: Pubmed

      • Measuring patient-centered outcomes in neurologic disease. Extending the Q-TWiST method. Arch Neurol. 1995 Aug; 52(8):754-62. View in: Pubmed

      • Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival. Cancer J Sci Am. 1995 Jul-Aug; 1(2):114-21. View in: Pubmed

      • Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995 06 29; 332(26):1738-43. View in: Pubmed

      • The Q-TWiST approach to assessing health-related quality of life in epilepsy. Qual Life Res. 1995 Apr; 4(2):135-41. View in: Pubmed

      • The quality of quality-of-life measurements. JAMA. 1995 Mar 15; 273(11):843; author reply 844-5. View in: Pubmed

      • The best available adjuvant treatments are within the framework of clinical trials. The International Breast Cancer Study Group. Isr J Med Sci. 1995 Feb-Mar; 31(2-3):144-54. View in: Pubmed

      • Quality-of-life assessment in clinical trials. Cancer Treat Res. 1995; 75:225-46. View in: Pubmed

      • A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med. 1994 Nov 03; 331(18):1181-7. View in: Pubmed

      • Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994 Nov 03; 331(18):1173-80. View in: Pubmed

      • The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. Ann Oncol. 1994 Oct; 5(8):717-24. View in: Pubmed

      • Parametric approaches to quality-adjusted survival analysis. International Breast Cancer Study Group. Biometrics. 1994 Sep; 50(3):621-31. View in: Pubmed

      • Present and future projects of the International Breast Cancer Study Group. Cancer. 1994 Aug 01; 74(3 Suppl):1139-49. View in: Pubmed

      • Understanding adjuvant chemotherapy for breast cancer. N Engl J Med. 1994 May 05; 330(18):1308-9. View in: Pubmed

      • Radiotherapy to the conserved breast: is it avoidable if the cancer is small? J Natl Cancer Inst. 1994 May 04; 86(9):652-4. View in: Pubmed

      • Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype. For the International (Ludwig) Breast Cancer Study Group. Ann Oncol. 1994 May; 5(5):409-14. View in: Pubmed

      • Testing tumor dormancy in breast cancer. J Natl Cancer Inst. 1994 Apr 06; 86(7):558. View in: Pubmed

      • Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol. 1994 Apr; 12(4):740-7. View in: Pubmed

      • Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. N Engl J Med. 1994 Mar 17; 330(11):738-43. View in: Pubmed

      • Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet. 1994 Feb 12; 343(8894):377-81. View in: Pubmed

      • Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: its effect on patient self-estimation. The International Breast Cancer Study Group. Ann Oncol. 1994 Jan; 5(1):65-74. View in: Pubmed

      • Roles of soluble fibronectin and beta 1 integrin receptors in the binding of Mycobacterium leprae to nasal epithelial cells. Clin Immunol Immunopathol. 1993 Dec; 69(3):266-71. View in: Pubmed

      • Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. International Breast Cancer Study Group. Control Clin Trials. 1993 Dec; 14(6):485-99. View in: Pubmed

      • Premenopausal oopherectomy versus CMF chemotherapy in stage II breast carcinoma. The International Breast Cancer Study Group (IBCSG) Lancet. 1993 Jul 31; 342(8866):305. View in: Pubmed

      • Central nervous system treatment in childhood acute lymphoblastic leukemia. Long-term follow-up of patients diagnosed between 1973 and 1985. Cancer. 1993 Jul 01; 72(1):261-70. View in: Pubmed

      • Sex differences in risk of second malignant tumours after Hodgkin's disease in childhood. Lancet. 1993 Jun 05; 341(8858):1428-32. View in: Pubmed

      • Cox regression models for quality adjusted survival analysis. Stat Med. 1993 May 30; 12(10):975-87. View in: Pubmed

      • Pediatric histiocytosis. Characterization, prognosis, and oral involvement. Am J Pediatr Hematol Oncol. 1993 May; 15(2):226-30. View in: Pubmed

      • Prognostic factors in medulloblastoma, including DNA ploidy. J Clin Oncol. 1993 Apr; 11(4):616-22. View in: Pubmed

      • Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. Blood. 1993 Mar 15; 81(6):1651-7. View in: Pubmed

      • Adjuvant therapy for breast cancer: understanding the overview. International Breast Cancer Study Group. J Clin Oncol. 1993 Mar; 11(3):580-5. View in: Pubmed

      • How to compare quality of life of breast cancer patients in clinical trials. International Breast Cancer Study Group. Recent Results Cancer Res. 1993; 127:221-33. View in: Pubmed

      • Adjuvant therapy of primary breast cancer: closing summary. Recent Results Cancer Res. 1993; 127:289-300. View in: Pubmed

      • From the overview to the patient: how to interpret meta-analysis data. Recent Results Cancer Res. 1993; 127:167-76. View in: Pubmed

      • Evaluation of effectiveness: Q-TWiST. The International Breast Cancer Study Group. Cancer Treat Rev. 1993; 19 Suppl A:73-84. View in: Pubmed

      • Adjuvant therapy of primary breast cancer. 4th International Conference on Adjuvant Therapy of Primary Breast Cancer St. Gallen, Switzerland. Ann Oncol. 1992 Dec; 3(10):801-7. View in: Pubmed

      • Meta-analysis: the fashion of summing-up evidence. Part II: Interpretations and uses. Ann Oncol. 1992 Nov; 3(9):683-91. View in: Pubmed

      • Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group). Ann Oncol. 1992 Nov; 3(9):733-40. View in: Pubmed

      • Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia. Cancer. 1992 Oct 15; 70(8):2208-13. View in: Pubmed

      • Meeting highlights: adjuvant therapy for primary breast cancer. J Natl Cancer Inst. 1992 Oct 07; 84(19):1479-85. View in: Pubmed

      • Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer. 1992 Jul 01; 70(1):201-6. View in: Pubmed

      • Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992 Jul; 10(7):1049-56. View in: Pubmed

      • Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. The AIDS Clinical Trials Group. Ann Intern Med. 1992 Jun 15; 116(12 Pt 1):961-6. View in: Pubmed

      • Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992 May; 10(5):696-705. View in: Pubmed

      • The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia. J Clin Oncol. 1992 May; 10(5):810-7. View in: Pubmed

      • Adjuvant treatment for breast cancer: the overview. BMJ. 1992 Apr 04; 304(6831):859-60. View in: Pubmed

      • A single perioperative adjuvant chemotherapy course for node-negative breast cancer: five-year results of trial V. International Breast Cancer Study Group (formerly Ludwig Group). J Natl Cancer Inst Monogr. 1992; (11):89-96. View in: Pubmed

      • Intensive sequential chemotherapy for children with acute myelogenous leukemia: VAPA, 80-035, and HI-C-Daze. Leukemia. 1992; 6 Suppl 2:48-51. View in: Pubmed

      • Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group). J Natl Cancer Inst Monogr. 1992; (11):127-35. View in: Pubmed

      • Behavioral effects of corticosteroids in children with acute lymphoblastic leukemia. Med Pediatr Oncol. 1992; 20(1):13-21. View in: Pubmed

      • Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. The International Breast Cancer Study Group. Eur J Cancer. 1992; 28(1):118-24. View in: Pubmed

      • Reporting and interpreting adjuvant therapy clinical trials. International Breast Cancer Study Group (formerly Ludwig Group). J Natl Cancer Inst Monogr. 1992; (11):59-69. View in: Pubmed

      • Models for weighing benefits and toxicities. Cancer Treat Res. 1992; 60:189-206. View in: Pubmed

      • Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update). Blood. 1991 Nov 15; 78(10):2514-9. View in: Pubmed

      • Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Münster and Dana-Farber Cancer Institute protocols. Ann Oncol. 1991 Nov-Dec; 2(10):745-9. View in: Pubmed

      • Helix pomatia in breast cancer. Lancet. 1991 Aug 31; 338(8766):580-1. View in: Pubmed

      • Meta-analysis: the fashion of summing-up evidence. Part I. Rationale and conduct. Ann Oncol. 1991 Jul; 2(7):461-8. View in: Pubmed

      • Axillary node micrometastases and breast cancer. Lancet. 1991 May 04; 337(8749):1110. View in: Pubmed

      • Chronic anterior uveitis in leprosy: an insidious cause of blindness. Br J Ophthalmol. 1991 May; 75(5):273-5. View in: Pubmed

      • Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group. Ann Intern Med. 1991 Apr 15; 114(8):621-8. View in: Pubmed

      • Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991 Mar 21; 324(12):808-15. View in: Pubmed

      • Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. Ann Oncol. 1991 Jan; 2(1):47-53. View in: Pubmed

      • Adjuvant therapy of breast cancer. International Breast Cancer Study Group. Eur J Cancer. 1991; 27(3):389-99. View in: Pubmed

      • Dentofacial development in long-term survivors of acute lymphoblastic leukemia. A comparison of three treatment modalities. Cancer. 1990 Dec 15; 66(12):2645-52. View in: Pubmed

      • Design considerations for AIDS trials. N Engl J Med. 1990 Nov 08; 323(19):1343-8. View in: Pubmed

      • Quality adjusted survival analysis. Stat Med. 1990 Nov; 9(11):1259-76. View in: Pubmed

      • Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. J Clin Oncol. 1990 Oct; 8(10):1707-14. View in: Pubmed

      • Occult axillary lymph-node micrometastases in breast cancer. Lancet. 1990 Sep 22; 336(8717):759. View in: Pubmed

      • Treatment of breast cancer in elderly patients. Lancet. 1990 Sep 01; 336(8714):564. View in: Pubmed

      • c-erbB-2 protein expression in node negative breast cancer. Ann Oncol. 1990 Jul; 1(4):263-8. View in: Pubmed

      • Adjuvant chemo-endocrine therapy in postmenopausal women with breast cancer and axillary-node metastases. Lancet. 1990 May 05; 335(8697):1099-100. View in: Pubmed

      • Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. International Breast Cancer Study Group. J Clin Oncol. 1990 Mar; 8(3):519-26. View in: Pubmed

      • Late effects of central nervous system treatment of acute lymphoblastic leukemia in childhood are sex-dependent. Dev Med Child Neurol. 1990 Mar; 32(3):238-48. View in: Pubmed

      • Improved methodology for analyzing local and distant recurrence. J Clin Oncol. 1990 Mar; 8(3):548-55. View in: Pubmed

      • The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol. 1990; 1(3):183-8. View in: Pubmed

      • More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials. Haematol Blood Transfus. 1990; 33:459-66. View in: Pubmed

      • Intensive sequential chemotherapy for children with acute myelogenous leukemia. Haematol Blood Transfus. 1990; 33:193-7. View in: Pubmed

      • Autologous bone marrow transplantation for acute lymphoblastic leukemia. J Clin Oncol. 1989 Nov; 7(11):1594-601. View in: Pubmed

      • Prognostic implications of cytogenetic studies in an intensively treated group of children with acute lymphoblastic leukemia. Blood. 1989 Nov 01; 74(6):2130-5. View in: Pubmed

      • A quality-of-life-oriented endpoint for comparing therapies. Biometrics. 1989 Sep; 45(3):781-95. View in: Pubmed

      • Clinical trials for clinicians. Chest. 1989 Jul; 96(1 Suppl):97S-101S. View in: Pubmed

      • The duration of a life of quality should become the focus of "quality-of-life" studies. J Clin Oncol. 1989 Apr; 7(4):542-4. View in: Pubmed

      • Critical review: methodology of adjuvant trials and interpretation of results. Recent Results Cancer Res. 1989; 115:236-8. View in: Pubmed

      • Comparison of adjuvant therapies using quality-of-life considerations. Int J Technol Assess Health Care. 1989; 5(3):401-13. View in: Pubmed

      • Methods for assessing treatment efficacy in trials for adjuvant therapy for breast cancer. Recent Results Cancer Res. 1989; 115:211-9. View in: Pubmed

      • Adjuvant chemo-endocrine therapy or endocrine therapy alone for postmenopausal patients: Ludwig Studies III and IV. Recent Results Cancer Res. 1989; 115:153-62. View in: Pubmed

      • Randomized perioperative therapy in operable breast cancer: the Ludwig Trial V. Recent Results Cancer Res. 1989; 115:43-53. View in: Pubmed

      • Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol. 1989 Jan; 7(1):36-44. View in: Pubmed

      • Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. N Engl J Med. 1988 Aug 18; 319(7):401-7. View in: Pubmed

      • Can a clinical trial be the treatment of choice for patients with cancer? J Natl Cancer Inst. 1988 Aug 17; 80(12):886-7. View in: Pubmed

      • Ophthalmic evaluation of survivors of acute lymphoblastic leukemia. Ophthalmology. 1988 Feb; 95(2):151-5. View in: Pubmed

      • Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. J Clin Oncol. 1988 Jan; 6(1):89-97. View in: Pubmed

      • Meta-analysis in clinical research. Ann Intern Med. 1988 Jan; 108(1):158-9. View in: Pubmed

      • Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of study 73-03 of the Radiation Therapy Oncology Group. Head Neck Surg. 1987 Sep-Oct; 10(1):19-30. View in: Pubmed

      • Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. Cancer Res. 1987 Sep 01; 47(17):4729-35. View in: Pubmed

      • Methotrexate/nitrous-oxide toxic interaction in perioperative chemotherapy for early breast cancer. Lancet. 1987 Jul 18; 2(8551):151. View in: Pubmed

      • Prognostic factors in childhood acute myelogenous leukemia. J Clin Oncol. 1987 Jul; 5(7):1026-32. View in: Pubmed

      • Interpretation of results from subset analyses within overviews of randomized clinical trials. Stat Med. 1987 Apr-May; 6(3):371-88. View in: Pubmed

      • Outcome of pregnancy in survivors of Wilms' tumor. JAMA. 1987 Jan 09; 257(2):216-9. View in: Pubmed

      • Postremission induction intensive sequential chemotherapy for children with AML--treatment results and prognostic factors. Haematol Blood Transfus. 1987; 30:88-92. View in: Pubmed

      • Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer. 1986 Dec 15; 58(12):2662-70. View in: Pubmed

      • A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol. 1986 Dec; 4(12):1772-9. View in: Pubmed

      • The concept of an overview of cancer clinical trials with special emphasis on early breast cancer. J Clin Oncol. 1986 Nov; 4(11):1696-703. View in: Pubmed

      • Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 1986 Sep 11; 315(11):657-63. View in: Pubmed

      • Adjuvant chemotherapy for breast cancer. A pooled estimate based on published randomized control trials. JAMA. 1986 Sep 05; 256(9):1148-59. View in: Pubmed

      • Depletion of T cells from human bone marrow using monoclonal antibodies and rabbit complement. A quantitative and functional analysis. Transplantation. 1986 Jul; 42(1):73-80. View in: Pubmed

      • First repeated bone scan in the observation of patients with operable breast cancer. J Clin Oncol. 1986 Mar; 4(3):389-94. View in: Pubmed

      • The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1986; 14(4):211-5. View in: Pubmed

      • Perioperative and conventionally timed chemotherapy in operable breast cancer: the Ludwig Breast Cancer Study V. Recent Results Cancer Res. 1986; 103:103-12. View in: Pubmed

      • Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies. NCI Monogr. 1986; (1):55-70. View in: Pubmed

      • Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Hum Pathol. 1985 Dec; 16(12):1212-8. View in: Pubmed

      • Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials. Cancer Treat Rep. 1985 Oct; 69(10):1139-46. View in: Pubmed

      • Adjuvant therapy in postmenopausal node-positive breast cancer. J Clin Oncol. 1985 Jul; 3(7):1045-7. View in: Pubmed

      • Endocrine adjuvant therapy for breast cancer. Lancet. 1985 Jun 01; 1(8440):1274. View in: Pubmed

      • Use of trimethoprim-sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia. Pediatr Infect Dis. 1985 May-Jun; 4(3):265-9. View in: Pubmed

      • Combination chemo-radiotherapy for residual, recurrent or inoperable carcinoma of the rectum: E.C.O.G. study (EST 3276). Int J Radiat Oncol Biol Phys. 1985 Apr; 11(4):765-71. View in: Pubmed

      • Radiation therapy alone or in combination with chemotherapy in the treatment of residual or inoperable carcinoma of the rectum and rectosigmoid or pelvic recurrence following colorectal surgery. Radiation Therapy Oncology Group study (76-16). Am J Clin Oncol. 1985 Apr; 8(2):118-27. View in: Pubmed

      • Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res. 1985 Feb; 45(2):499-503. View in: Pubmed

      • Methodological and statistical aspects in perioperative chemotherapy trials. Recent Results Cancer Res. 1985; 98:53-63. View in: Pubmed

      • Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients. J Clin Oncol. 1984 May; 2(5):425-31. View in: Pubmed

      • Ludwig Breast Cancer trial LBCS III: chemo- and endocrine adjuvant treatment in postmenopausal patients. Recent Results Cancer Res. 1984; 96:102-9. View in: Pubmed

      • Second neoplasms after Wilms' tumor in childhood. J Natl Cancer Inst. 1983 Dec; 71(6):1205-9. View in: Pubmed

      • Analysis of survival by tumor response. J Clin Oncol. 1983 Nov; 1(11):710-9. View in: Pubmed

      • Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983 Nov; 43(11):5601-7. View in: Pubmed

      • Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood. 1983 Aug; 62(2):315-9. View in: Pubmed

      • The role of radiation therapy in the palliation of metastatic genitourinary tract carcinomas. A study of the Radiation Therapy Oncology Group. Cancer. 1983 Jul 01; 52(1):25-9. View in: Pubmed

      • The influence of surgery and radiation therapy on patients with brain metastases. Int J Radiat Oncol Biol Phys. 1983 May; 9(5):623-7. View in: Pubmed

      • Risk factors for thyroid abnormalities after neck irradiation for childhood cancer. Am J Med. 1983 Feb; 74(2):272-80. View in: Pubmed

      • The treatment of acute myelogenous leukemia in children and adults: VAPA update. Haematol Blood Transfus. 1983; 28:41-5. View in: Pubmed

      • Experience of the Eastern Cooperative Oncology Group with doxorubicin as a single agent in patients with previously untreated breast cancer. Cancer Treat Rep. 1982 Jul; 66(7):1594-5. View in: Pubmed

      • Does preoperative irradiation increase the rate of surgical complications in carcinoma of the head and neck? A Radiation Therapy Oncology Group Report. Cancer. 1982 Mar 15; 49(6):1297-301. View in: Pubmed

      • Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1981 Dec; 7(12):1633-8. View in: Pubmed

      • Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favorable prognosis. Cancer. 1981 Oct 15; 48(8):1749-53. View in: Pubmed

      • Antiemetic effect of intramuscular levonantradol in patients receiving anticancer chemotherapy. J Clin Pharmacol. 1981 Aug-Sep; 21(S1):43S-50S. View in: Pubmed

      • The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1981 Jul; 7(7):891-5. View in: Pubmed

      • The palliation of hepatic metastases: results of the Radiation Therapy Oncology Group pilot study. Int J Radiat Oncol Biol Phys. 1981 May; 7(5):587-91. View in: Pubmed

      • Ovarian failure in long-term survivors of childhood malignancy. Am J Obstet Gynecol. 1981 Jan; 139(1):62-6. View in: Pubmed

      • Trials of single-agent and combination chemotherapy for advanced cancer of the pancreas. Cancer Treat Rep. 1981 Jan-Feb; 65(1-2):65-8. View in: Pubmed

      • Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Cancer. 1980 Nov 15; 46(10):2149-53. View in: Pubmed

      • A controlled evaluation of combined radiation and bleomycin therapy for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 1980 Jul; 6(7):821-6. View in: Pubmed

      • Randomized preoperative and postoperative radiation therapy for patients with carcinoma of the head and neck: preliminary report. Laryngoscope. 1980 Jun; 90(6 Pt 1):930-45. View in: Pubmed

      • Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. Blood. 1980 Mar; 55(3):395-402. View in: Pubmed

      • Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: Radiation Therapy Oncology Group Brain Metastases Study I and II. Cancer. 1980 Feb 15; 45(4):679-83. View in: Pubmed

      • Basilic vein to brachial artery, arteriovenous fistula for long-term hemodialysis: a five year follow-up. Proc Clin Dial Transplant Forum. 1980; 10:126-9. View in: Pubmed

      • The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980 Jan; 6(1):1-9. View in: Pubmed

      • Designing and analyzing clinical trials which allow institutions to randomize patients to a subset of the treatments under study. Biometrics. 1979 Dec; 35(4):825-9. View in: Pubmed

      • Evaluation of randomized preoperative and postoperative radiation therapy for supraglottic carcinoma. Preliminary report. Ann Otol Rhinol Laryngol. 1978 Sep-Oct; 87(5 Pt 1):686-91. View in: Pubmed

      • Veillonella parvula septicemia and osteomyelitis. Ann Intern Med. 1977 Jan; 86(1):63-4. View in: Pubmed

      • The use of basilic vein and brachial artery as an A-V fistula for long term hemodialysis. J Surg Res. 1976 Apr; 20(4):373-6. View in: Pubmed

      • Letter: Acid-fast smears in tuberculosis detection. Ann Intern Med. 1976 Mar; 84(3):344. View in: Pubmed

      Locations

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue CLS 11072 Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue CLS 11072 Boston, MA 02215
      Get Direction
      42.3374, -71.1082